Adding know-how to the existing CRO service, we are proud of the highest level in Korea in the CNS field   

NeuroVenti, which is preparing for a phase 2 clinical trial for NV01-A02 a candidate for autism treatment, announced on May 24 that it had successfully promoted CDRO services for CNS diseases through a booth event at the 45th Korea Non-Clinical Trial Research Society workshop held under the theme of "Man Can Be Destroyed, But Never Defeated By Cancer" at the Suwon Convention Center.  

The workshop, which was held during the "2024 Gwanggyo Bio Week" (May 22-24), sponsored by Suwon Special City, which is preparing for a new leap through the pharmaceutical bio industry, with the Korea Pharmaceutical Bio Association, presented a total of 18 themes, including six keynote lectures and four divisions and 12 lectures. Along with this, more than 70 companies including pharmaceutical, bio, CRO, hospitals and research institutes will open booths, and it is the largest non-clinical trial workshop in Korea with 1,200 people attending.  

Based on the expertise and know-how in the field of CNS obtained while researching and developing brain disease treatments, NeuroVenti launched Korea's best non-clinical CDRO service specializing in CNS diseases last year, connecting with several big partners.  

In response, Director Kwon Kyung-ja of NeuroVenti said, "From this year, we will further expand and upgrade CDRO services, such as securing additional professionals," and is preparing for a bigger leap forward with new partners. As attention is being paid to NeuroVenti's move this year, we look forward to the news of the approval of the upcoming phase 2 clinical trial for NV01-A02, a candidate for autism treatment.